We reviewed our experience with adding mifepristone to the protocol for the termination of pregnancy up to 24 weeks of gestation by intra-amniotic ethacridine lactate.
The study consisted of women who presented for the termination of a second-trimester pregnancy between August 2000 and July 2008.
Of 1245 women who requested a termination of a second-trimester pregnancy, 744 women underwent the induction of abortion by intra-amniotic ethacridine lactate with mifepristone (mifepristone group), and 501 received intra-amniotic ethacridine lactate alone (control group). The proportion of women who delivered within 24 h was 25.94% in the mifepristone group and 10.18% in the control group (p<.001); the failure rate of abortion was 5.38% in the mifepristone group and 4.99% in the control group (p<.001). There was no significant difference in the complication rate between the two groups. The rate of cervical laceration was 0.54% in the mifepristone group and 0.60% in the control group (p=.9315). The rate of retained placental tissue was 6.99% in the mifepristone group and 6.19% in the control group (p=.1112). Nausea was reported by 34.0% of women in the mifepristone group and none in the control group.
The addition of mifepristone to ethacridine lactate may shorten the induction-to-abortion time compared with the use of ethacridine lactate alone without increasing the number of complications.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- World Health Organization medical methods for termination of pregnancy. WHO technical report series 871. World Health Organization, Geneva1997
- Progesterone receptor blockage. Effect on uterine contractility and early pregnancy.Contraception. 1985; 32: 45-51
- Mifepristone (RU 486) and second-trimester termination.Lancet. 1987; 2: 1405
- The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin.Br J Obstet Gynaecol. 1988; 95: 126-134
- Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. A large-scale French experience.N Engl J Med. 1990; 322: 645-648
- The use of antiprogestin (RU 486) for termination of second trimester pregnancy.Acta Obstet Gynecol Scand. 1991; 70: 199-203
- Intraamniotic injection of ethacridine for second-trimester induction of labor.Obstet Gynecol. 1983; 61: 733-736
- Intraamniotic ethacridine lactate instillation versus vaginal PGE1 in second trimester termination of pregnancy.Eur J Obstet Gynecol Reprod Biol. 2006; 126: 193-196
- Mifepristone in abortion care.Semin Reprod Med. 2005; 23: 82-91
- Mifepristone for induction of labour (Cochrane Review).Cochrane Library. 2000; (Oxford: CD002865)
- The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion.Contraception. 2006; 74: 26-30
- Intrauterine administration of drugs for termination of pregnancy in the second trimester.Baillieres Clin Obstet Gynaecol. 1990; 4: 327-349
- Prostaglandins and thromboxanes in amniotic fluid during rivanol-induced abortion and labour.Prostaglandins. 1980; 19: 791-803
- Increase of the prostaglandin precursor, arachidonic acid, in amniotic fluid during spontaneous labour.Br J Obstet Gynaecol. 1977; 84: 937-940
- On the mechanism of action of ethodin in inducing myometrium contractions.Gen Pharmacol. 1997; 28: 381-385
- Mifepristone-induced cervical ripening: structural, biomechanical, and molecular events.Am J Obstet Gynecol. 2006; 194: 1391-1398
- Second trimester medical abortion with mifepristone and gemeprost: a review of 956 cases.Contraception. 2001; 64: 29-32
Published online: July 15, 2011
Accepted: June 1, 2011
Received in revised form: May 31, 2011
Received: December 18, 2010
© 2012 Elsevier Inc. Published by Elsevier Inc. All rights reserved.